拉罗替尼治疗TRK融合儿童肿瘤中国专家共识  

Chinese expert consensus on clinical application of larotrectinib for the treatment of pediatric tumors with TRK fusion

作　　者：中国抗癌协会小儿肿瘤专业委员会 中国研究型医院学会儿童肿瘤专业委员会 王焕民 赵强 张翼鷟 成海燕[2] 齐丽莎 路素英[4] diatric Oncology Committee of China Anti-Cancer Association;Chinese Research Hospital Association;Huanmin Wang;Qiang Zhao;Yizhuo Zhang

机构地区：[1]不详 [2]国家儿童医学中心,首都医科大学附属北京儿童医院 [3]天津医科大学肿瘤医院 [4]中山大学肿瘤防治中心

出　　处：《中国肿瘤临床》2023年第17期865-872,共8页Chinese Journal of Clinical Oncology

摘　　要：神经营养酪氨酸受体激酶(neurotrophic receptor tyrosine kinase,NTRK)融合在儿童肿瘤的发生率显著高于成人。某些特定瘤种中,如婴儿型纤维肉瘤(infantile fibrosarcoma,IFS)、先天性中胚叶细胞肾瘤(congenital mesoblastic nephroma,CMN)和累及乳腺或唾液腺的分泌性癌,儿童肿瘤患者NTRK基因融合存在高频异常。拉罗替尼(larotrectinib)是一代高选择性口服原肌球蛋白受体激酶(tropomyosin receptor kinase,TRK)抑制剂,其胶囊剂型和口服液制剂已在中国上市。中国抗癌协会小儿肿瘤专业委员会和中国研究型医院学会基于循证医学证据制定本共识,旨在为中国儿科医师应用拉罗替尼提供规范指导,并为进一步开展相关临床研究提供思路。Neurotrophic receptor tyrosine kinase(NTRK)gene fusions are found at a higher frequency,predominantly in pediatric tumors than in adult tumors.In some specific pediatric tumor types,including infantile fibrosarcoma(IFS),congenital mesoblastic nephroma(CMN),and secretory carcinoma of the breast or salivary glands,NTRK gene fusions are present with an abnormally high frequency.Larotrectinib is a first-generation,highly selective oral tropomyosin receptor kinase inhibitor(TRK).In China,it is currently marketed as a capsule dosage form and oral liquid preparation.The Pediatric Oncology Committee of China Anti-Cancer Association and Chinese Research Hospital Association formulated this consensus based on evidence-based medicine,aiming to provide normative guidance for pediatric clinicians to use larotrectinib and provide ideas for further clinical research.

关 键 词：NTRK融合基因 儿童肿瘤 拉罗替尼 TRK抑制剂 

分 类 号：R730[医药卫生—肿瘤]